Only TIM-3+, but not TIM-3− AML LSCs were able to reconstitute human AML in xenotransplantation assays, and TIM-3 blocking mAb treatment inhibited AML engraftment and reduced disease burden in already established xenografts (228). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.